NAC Attack

NAC Attack: A Multicenter, Placebo-Controlled Clinical Trial To Test Oral N-Acetylcysteine in Patients

NAC is a strong antioxidant that reduces oxidative damage. NAC Attack is a randomized, placebo-controlled multicenter trial that will test whether NAC can slow progression of RP. The results are critical to the RP community because if NAC proves beneficial it will mean lifelong treatment with NAC for patients with RP. We understand the anxiety and concerns that RP causes, but it is best to avoid self-medication with supplements.

Frequently Asked Questions

NAC Attack Video FAQ

English | Closed captioning is available by clicking the "CC" icon in the bottom right corner. Select the language you want from the list of available languages. 

Nederlands | Tik op Ondertiteling "CC." Selecteer de taal waarin je de ondertiteling wilt zien.

Français | Appuyez sur Sous-titres "CC ". Sélectionnez la langue dans laquelle vous souhaitez afficher les sous-titres. 

Deutsch Tippe auf das Untertitelsymbol "CC". Wähle die Sprache aus, in der die Untertitel angezeigt werden sollen.

Español Toca Subtítulos "CC". Elige el idioma en el que quieras ver los subtítulos.

NAC Attack | Important Things To Remember

NAC Attack | Caring for Your Medication

NAC Attack | Using the Medication

NAC Attack | What To Expect at Your Health-care Visits

NAC Attack | What To Do if You Have a Question

Clinical Sites

NAC Attack clinical sites have been chosen and screening will begin in early 2023. If you are interested in participating in this study, contact the site location that is convenient for you now to assess potential eligibility.

Supporting Organizations

  • Zambon SpA, Milan, Italy
  • Usher 2020
  • Fighting Blindness Canada
  • Retina UK

NAC Attack Leadership

Study Chairman's Office

Coordinating Center

  • Director and Senior Biostatistician: Xiangrong Kong, Ph.D.
  • Project Manager: Yanzhao (Izzie) Wang
  • Informatics Director: Kurt Dreger
  • Finance: Assa Cisse and Lee Rorke
  • Biostatistician: Minchan (Daisy) Shi
  • Research Fellow: Folahan Ibukun
  • Research Assistant: Jack Liu

NAC Attack Data Safety Monitoring Committee (DSMC)

Chair: Steven Piantadosi, M.D., Ph.D.
Biostatistics and Oncology, Brigham and Women's Hospital, Harvard University

Elise Heon, M.D.
Ophthalmology and Vision Sciences, University of Toronto

Judith Hochman, M.D.
Cardiology and Clinical Trials, New York University

David C. Musch Ph.D., M.P.H.,
Epidemiology and Ophthalmology, University of Michigan

Stephen H. Tsang, M.D., Ph.D.
Ophthalmology, and Pathology and Cell Biology, Columbia University

David N. Zacks, M.D., Ph.D.
Ophthalmology and Visual Sciences, University of Michigan

Alison Bateman-House, Ph.D.
Population Health, New York University


Contact the NAC Attack team to learn more.